Literature DB >> 26186678

ADAMTS13 and von Willebrand factor interactions.

Catherine B Zander1, Wenjing Cao, X Long Zheng.   

Abstract

PURPOSE OF REVIEW: ADAMTS13 is a zinc-containing metalloprotease that cleaves von Willebrand factor (VWF). Deficiency of plasma ADAMTS13 activity is accountable for a potentially fatal blood disorder thrombotic thrombocytopenic purpura (TTP). Understanding of ADAMTS13-VWF interaction is essential for developing novel treatments to this disorder. RECENT
FINDINGS: Despite the proteolytic activity of ADAMTS13 being restricted to the metalloprotease domain, the ancillary proximal C-terminal domains including the disintegrin domain, first TSP-1 repeat, cysteine-rich region, and spacer domain are all required for cleavage of VWF and its analogs. Recent studies have added to our understandings of the role of the specific regions in the disintegrin domain, the cysteine-rich domain, and the spacer domain responsible for its interaction with VWF. Additionally, regulative functions of the distal portion of ADAMTS13 including the TSP-1 2-8 repeats and the CUB domains have been proposed. Finally, fine mapping of anti-ADAMTS13 antibody epitopes have provided further insight into the essential structural elements in ADAMTS13 for VWF binding and the mechanism of autoantibody-mediated TTP.
SUMMARY: Significant progress has been made in our understandings of the structure-function relationship of ADAMTS13 in the past decade. To further investigate ADAMTS13-VWF interactions for medical applications, these interactions must be studied under physiological conditions in vivo.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26186678      PMCID: PMC4824554          DOI: 10.1097/MOH.0000000000000169

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  97 in total

Review 1.  von Willebrand factor.

Authors:  J E Sadler
Journal:  J Biol Chem       Date:  1991-12-05       Impact factor: 5.157

2.  Allosteric activation of ADAMTS13 by von Willebrand factor.

Authors:  Joshua Muia; Jian Zhu; Garima Gupta; Sandra L Haberichter; Kenneth D Friedman; Hendrik B Feys; Louis Deforche; Karen Vanhoorelbeke; Lisa A Westfield; Robyn Roth; Niraj Harish Tolia; John E Heuser; J Evan Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-15       Impact factor: 11.205

3.  ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences.

Authors:  H B Feys; F Liu; N Dong; I Pareyn; S Vauterin; N Vandeputte; W Noppe; C Ruan; H Deckmyn; K Vanhoorelbeke
Journal:  J Thromb Haemost       Date:  2006-05       Impact factor: 5.824

4.  Reduced von Willebrand factor-cleaving protease (ADAMTS13) activity in acute myocardial infarction.

Authors:  K Kaikita; K Soejima; M Matsukawa; T Nakagaki; H Ogawa
Journal:  J Thromb Haemost       Date:  2006-08-08       Impact factor: 5.824

5.  ADAMTS13 gene deletion enhances plasma high-mobility group box1 elevation and neuroinflammation in brain ischemia-reperfusion injury.

Authors:  Masayuki Fujioka; Takafumi Nakano; Kazuhide Hayakawa; Keiichi Irie; Yoshiharu Akitake; Yuya Sakamoto; Kenichi Mishima; Carl Muroi; Yasuhiro Yonekawa; Fumiaki Banno; Koichi Kokame; Toshiyuki Miyata; Kenji Nishio; Kazuo Okuchi; Katsunori Iwasaki; Michihiro Fujiwara; Bo K Siesjö
Journal:  Neurol Sci       Date:  2012-01-03       Impact factor: 3.307

6.  Characterization of a core binding site for ADAMTS-13 in the A2 domain of von Willebrand factor.

Authors:  Jing-Jiang Wu; Kazuo Fujikawa; Brad A McMullen; Dominic W Chung
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-22       Impact factor: 11.205

7.  A functional calcium-binding site in the metalloprotease domain of ADAMTS13.

Authors:  Michelle D Gardner; Chan K N K Chion; Rens de Groot; Anuja Shah; James T B Crawley; David A Lane
Journal:  Blood       Date:  2008-12-01       Impact factor: 22.113

8.  von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke.

Authors:  Bing-Qiao Zhao; Anil K Chauhan; Matthias Canault; Ian S Patten; Janie J Yang; Michael Dockal; Friedrich Scheiflinger; Denisa D Wagner
Journal:  Blood       Date:  2009-08-17       Impact factor: 22.113

Review 9.  Biochemistry and genetics of von Willebrand factor.

Authors:  J E Sadler
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

Review 10.  Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor.

Authors:  James T B Crawley; Rens de Groot; Yaozu Xiang; Brenda M Luken; David A Lane
Journal:  Blood       Date:  2011-06-29       Impact factor: 22.113

View more
  15 in total

1.  Phylogenetic and functional analysis of ADAMTS13 identifies highly conserved domains essential for allosteric regulation.

Authors:  Joshua Muia; Jian Zhu; Suellen C Greco; Karen Vanhoorelbeke; Garima Gupta; Lisa A Westfield; J Evan Sadler
Journal:  Blood       Date:  2019-01-30       Impact factor: 22.113

2.  Identification of extant vertebrate Myxine glutinosa VWF: evolutionary conservation of primary hemostasis.

Authors:  Marianne A Grant; David L Beeler; Katherine C Spokes; Junmei Chen; Harita Dharaneeswaran; Tracey E Sciuto; Ann M Dvorak; Gianluca Interlandi; José A Lopez; William C Aird
Journal:  Blood       Date:  2017-09-12       Impact factor: 22.113

3.  Distinguishing Alzheimer's Disease Patients and Biochemical Phenotype Analysis Using a Novel Serum Profiling Platform: Potential Involvement of the VWF/ADAMTS13 Axis.

Authors:  Jay S Hanas; James R S Hocker; Christian A Vannarath; Megan R Lerner; Scott G Blair; Stan A Lightfoot; Rushie J Hanas; James R Couch; Linda A Hershey
Journal:  Brain Sci       Date:  2021-04-30

4.  Adamts18 deletion results in distinct developmental defects and provides a model for congenital disorders of lens, lung, and female reproductive tract development.

Authors:  Dalya Ataca; Marian Caikovski; Alessandra Piersigilli; Alexandre Moulin; Charaf Benarafa; Sarah E Earp; Yakir Guri; Corinne Kostic; Yvan Arsenijevic; Raija Soininen; Suneel S Apte; Cathrin Brisken
Journal:  Biol Open       Date:  2016-11-15       Impact factor: 2.422

5.  Removal of the C-Terminal Domains of ADAMTS13 by Activated Coagulation Factor XI induces Platelet Adhesion on Endothelial Cells under Flow Conditions.

Authors:  Kathleen S Garland; Stéphanie E Reitsma; Toshiaki Shirai; Jevgenia Zilberman-Rudenko; Erik I Tucker; David Gailani; András Gruber; Owen J T McCarty; Cristina Puy
Journal:  Front Med (Lausanne)       Date:  2017-12-20

6.  Upshaw-Schulman syndrome-associated ADAMTS13 variants possess proteolytic activity at the surface of endothelial cells and in simulated circulation.

Authors:  Anton Letzer; Katja Lehmann; Christian Mess; Gesa König; Tobias Obser; Sven Peine; Sonja Schneppenheim; Ulrich Budde; Stefan W Schneider; Reinhard Schneppenheim; Maria A Brehm
Journal:  PLoS One       Date:  2020-05-04       Impact factor: 3.240

7.  Severe primary refractory thrombotic thrombocytopenic purpura (TTP) in the post plasma exchange (PEX) and rituximab era.

Authors:  Sowmya Goranta; Smit S Deliwala; Tarek Haykal; Ghassan Bachuwa
Journal:  BMJ Case Rep       Date:  2020-06-11

Review 8.  ADAM and ADAMTS Family Proteins and Snake Venom Metalloproteinases: A Structural Overview.

Authors:  Soichi Takeda
Journal:  Toxins (Basel)       Date:  2016-05-17       Impact factor: 4.546

9.  Von Willebrand factor with increased binding capacity is associated with reduced platelet aggregation but enhanced agglutination in COVID-19 patients: another COVID-19 paradox?

Authors:  Franco Ruberto; Antonio Chistolini; Mariaignazia Curreli; Giacomo Frati; Antonino G M Marullo; Giuseppe Biondi-Zoccai; Massimo Mancone; Sebastiano Sciarretta; Fabio Miraldi; Francesco Alessandri; Giancarlo Ceccarelli; Francesco Barone; Cristina Santoro; Domenico Alvaro; Francesco Pugliese; Fabio M Pulcinelli
Journal:  J Thromb Thrombolysis       Date:  2021-01-02       Impact factor: 2.300

Review 10.  ADAMTS-13 and von Willebrand factor: a dynamic duo.

Authors:  K South; D A Lane
Journal:  J Thromb Haemost       Date:  2017-12-02       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.